CClinicalTrials.gg
CompletedNCT05516147Updated Mar 21, 2025Results posted

SAFE at Home: A Service to Provide Social Engagement to Community-Dwelling Persons With Dementia

An interventional study of SAFE at Home in Alzheimer Disease, Dementia and Dementia, Vascular, sponsored by Hopeful Aging. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Hopeful Aging · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The proposed Phase 1 study will involve initial development and evaluation of a new service called Social Activities For Engagement at Home or SAFE at Home (SaH). SaH will enable PWD to participate in videoconference-based group activities with their peers-i.e., other PWD. SaH sessions will be facilitated by highly trained "Engagement Professionals," who will be SaH staff members that have a background in recreation therapy, activity coordination, or a similar field. The proposed study has three Specific Aims: Aim 1. Develop an Alpha version of the SaH app, including app infrastructure and preliminary activity content for live group sessions, as well as staff training and coaching modules. Aim 2. Examine the app's acceptability/feasibility (by assessing attendance, session length, and engagement/affect). Aim 3. Examine satisfaction with the app by directly eliciting feedback from PWD and life enrichment staff.

Read the detailed description

Aim 1. Develop an Alpha version of the SAFE at Home app, including app infrastructure and preliminary activity content for live group sessions, as well as staff training and coaching modules. During Months 1-6, the Development Team (DT) will create the initial product design and prototype for use in the study. The study team will engage 5 PWD, 5 family members, and 5 activity professionals in focus groups to review the mockups and to understand end user preferences in terms of user experience and activity content. This will be the only involvement for these participants. New participants will be recruited for the quasi-experiment (described below). Aim 2. Examine the app's acceptability/feasibility (by assessing attendance, session length, and engagement/affect) During Months 5-10, the Experimental Team (ET) will utilize a quasi-experimental pre-post design (i.e., baseline vs. treatment / post-treatment) to conduct a two-month long acceptability and feasibility trial of SaH. During this trial 15 PWD, 15 Family Members, and 5 Life Enrichment professionals will use the product to determine functionality, acceptability, and feasibility. Baseline and Onboarding (Month 7). PWD: During the 4-week baseline period, the ET will collect the following data. PWD Demographics, medications, diagnoses, and type of dementia will be collected via proxy (family member) interview. The following assessments will be administered directly: the Short Portable Mental Status Questionnaire (SPMSQ-T), the Dementia Quality of Life Scale (DEMQOL), the Geriatric Depression Scale-Short Form (GDS-SF), and the UCLA Loneliness Scale (ULS). Researchers will interview family members (FMs) using the Neuropsychiatric Inventory-Nursing Home (NPI-NH). Using the Menorah Park Engagement Scale. researchers will observe PWD engagement and affect via videoconference on four days. This will allow us to determine "normal/baseline" engagement levels for each PWD and serve as a comparison for SaH. At the conclusion of the Baseline data collection, the ET will use the Get to Know You Portal with each PWD to determine their Cognitive and Communication levels as well as their interests. For the purposes of testing the feasibility of the SaH intervention, all group assignments will be made solely through the use of SaH tools. Staff Demographics will be collected. Staff will also take pre-training quizzes prior to taking the training modules. Family Members (FMs) will provide demographic information and serve as proxies for the above PWD measures. Intervention Period (Months 8-9). PWD: During the 8-week intervention period, PWD will participate in SaH sessions through the Social Engagement Portal. Sessions will occur twice per week and last 30-45 minutes. Staff: Staff will take the training modules developed in Aim 1 and will also run a simulated group and provide feedback. FMs will be involved simply by helping set up the hardware and helping their loved one with technical issues as needed (e.g., reconnecting to the videoconference if the connection is lost). Post Intervention Period (Month 10). PWD: The DEMQOL, GDS-SF, ULS, and NPI-NH will be re-administered at Post-Intervention, allowing us to investigate possible long-term effects. Changes on these longer-term measures are not expected in this Phase 1 study. However, data will be used to conduct power analyses for Phase 2. Staff: Staff will take post-training quizzes after completing the training modules. FMs will serve as proxies for some of the above measures. Milestones. This Aim will be considered successfully met if: (1) At least 85% of PWD agree to take part in 80% of the sessions. (2) Mean session length is least 25 minutes. (3) PWD exhibit higher levels of positive engagement/affect and lower levels of negative engagement during SaH sessions, as compared to baseline (based upon the MPES). This will be assessed by using paired samples t-tests. With the proposed sample, there will be a power of 99% to detect effects. A detailed power analysis is included in Clinical Trials-Statistical Design and Power. (4) Staff show an increase in knowledge after taking the training modules, based upon paired samples t-tests (pre-training quizzes vs. post-training quizzes). Aim 3. Examine satisfaction with the app by directly eliciting feedback from PWD and life enrichment staff. Overview: This Aim occurs concurrently with the Intervention Period for Aim 2 and utilizes the same sample and procedures-it merely tracks separate outcomes. Intervention Period (Months 8-9). PWD: During the intervention period, PWD will answer questions related to satisfaction at the end of each session. Staff: Staff will answer satisfaction questions related to the course and to the app (after the run a simulated group). FMs will answer satisfaction questions at the end of the study. Challenges. Since this aim occurs concurrently with Aim 2, no distinct challenges related solely to Aim 3 are expected. Milestones: This Aim will be considered successfully met if PWD, staff members, and FMs report high satisfaction with the app, defined as 85% being satisfied or very satisfied.

02

Conditions studied

  • Alzheimer Disease
  • Dementia
  • Dementia, Vascular
  • Dementia, Mixed

Keywords

  • non-pharmacological intervention
  • psychosocial
03

In context

Alzheimer Disease

3,675 studies on the registry are indexed under Alzheimer Disease; 869 are open to participants now.

This study's enrollment of 12 is below the median of 70 across 2,805 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Hopeful Aging is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PWD Inclusion Criteria:

  • 65+ years old
  • speak and read conversational English
  • diagnosed with dementia (any type)

PWD Exclusion Criteria:

-signs of rapid cognitive decline or physical deterioration over the last six months, as evidenced by medical records.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment

    SAFE at Home Intervention

    Behavioral: SAFE at Home

Interventions

  • BehavioralSAFE at Home

    SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.

06

What researchers measure

Primary outcomes

  1. Constructive Engagement Mean on Menorah Park Engagement Scale

    Constructive Engagement on the Menorah Park Engagement Scale (MPES) is defined as doing or commenting on something related to the target activity. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Constructive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Constructive Engagement mean of 0.85 for standard programming.

    Time frame: Treatment (Weeks 5-10)

  2. Passive Engagement Mean on Menorah Park Engagement Scale

    Passive Engagement on the Menorah Park Engagement Scale is defined as listening or watching something related to the target activity. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Passive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Passive Engagement mean of 1.06 for standard programming.

    Time frame: Treatment (Weeks 5-10)

  3. Other Engagement Mean on Menorah Park Engagement Scale

    Other Engagement on the Menorah Park Engagement Scale is defined as doing, commenting, listening, or watching something NOT related to the target activity. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Other Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Other Engagement mean of 0.42 for standard programming.

    Time frame: Treatment (Weeks 5-10)

  4. Non Engagement Mean on Menorah Park Engagement Scale

    Non-Engagement on the Menorah Park Engagement Scale is defined as sleeping and/or staring into space. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Non Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Non Engagement mean of 0.40 for standard programming.

    Time frame: Treatment (Weeks 5-10)

  5. Pleasure Mean on Menorah Park Engagement Scale

    Pleasure on the Menorah Park Engagement Scale is defined as clearly observable laughing or smiling.For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Non Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Non Engagement mean of 0.28 for standard programming.

    Time frame: Treatment (Weeks 5-10)

Secondary outcomes

  1. Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)

    The Dementia Related Quality of Life Scale is a 28 item scale that examines quality of life in persons with dementia. The score ranges for 28 to 112. Higher scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

  2. Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)

    The NPI-NH examines 10 types of neuropsychiatric symptoms in persons with dementia, with the FxS score looking creating a composite score that takes into account frequency and severity of the symtoms. The score ranges from 0 to 120. Lower scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

  3. Change From Baseline to Treatment on the University of California, Los Angels (UCLA) Loneliness Scale

    The UCLA Loneliness Scale is a widely used psychological tool designed to measure an individual's subjective feelings of loneliness and social isolation. The 20-item version consists of statements related to social connections, with responses typically rated on a four-point Likert scale (e.g., "Never," "Rarely," "Sometimes," "Often"). Scoring involves summing item responses, with higher scores indicating greater levels of loneliness. The range of total possible score is 20 (least amount of loneliness) to 80 (most amount of loneliness).

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

  4. Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)

    The 15-item Geriatric Depression Scale (GDS-SF) is a screening tool used to assess depressive symptoms in older adults. Each item is answered with a "Yes" or "No"\*\* response, with a total score ranging from 0 to 15, where higher scores indicate greater depressive symptoms. A score of 5 or more\*\* suggests possible depression, warranting further clinical evaluation.

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

07

Results

Posted Mar 21, 2025

Participant flow

Participant flow — Overall Study
MilestoneTreatment
Started10
Completed8
Not completed2
Withdrew: Scheduling conflicts made it impossible for them to participate2

Outcome measures

PrimaryConstructive Engagement Mean on Menorah Park Engagement Scale

Constructive Engagement on the Menorah Park Engagement Scale (MPES) is defined as doing or commenting on something related to the target activity. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Constructive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Constructive Engagement mean of 0.85 for standard programming.

Time frame:
Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Constructive Engagement Mean on Menorah Park Engagement Scale
score on a scaleTreatment
Constructive Engagement Mean on Menorah Park Engagement Scale1.22 ± 0.32
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01 (A one-sample t-test was used to assess whether the mean was different from a known Constructive Engagement mean of 0.85 for standard programming.)
PrimaryPassive Engagement Mean on Menorah Park Engagement Scale

Passive Engagement on the Menorah Park Engagement Scale is defined as listening or watching something related to the target activity. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Passive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Passive Engagement mean of 1.06 for standard programming.

Time frame:
Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Passive Engagement Mean on Menorah Park Engagement Scale
score on a scaleTreatment
Passive Engagement Mean on Menorah Park Engagement Scale1.65 ± 0.25
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01 (A one-sample t-test was used to assess whether the mean was different from a known Passive Engagement mean of 1.06 for standard programming.)A one-sample t-test was used to assess whether the mean was different from a known Passive Engagement mean of 1.06 for standard programming.
PrimaryOther Engagement Mean on Menorah Park Engagement Scale

Other Engagement on the Menorah Park Engagement Scale is defined as doing, commenting, listening, or watching something NOT related to the target activity. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Other Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Other Engagement mean of 0.42 for standard programming.

Time frame:
Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Other Engagement Mean on Menorah Park Engagement Scale
score on a scaleTreatment
Other Engagement Mean on Menorah Park Engagement Scale0.17 ± 0.36
Statistical analysis
  • Treatment · t-test, 2 sided · p = 0.06 (A one-sample t-test was used to assess whether the mean was different from a known Other Engagement mean of 0.42 for standard programming.)A one-sample t-test was used to assess whether the mean was different from a known Other Engagement mean of 0.42 for standard programming.
PrimaryNon Engagement Mean on Menorah Park Engagement Scale

Non-Engagement on the Menorah Park Engagement Scale is defined as sleeping and/or staring into space. For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Non Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Non Engagement mean of 0.40 for standard programming.

Time frame:
Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Non Engagement Mean on Menorah Park Engagement Scale
score on a scaleTreatment
Non Engagement Mean on Menorah Park Engagement Scale0.001 ± 0.003
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01
PrimaryPleasure Mean on Menorah Park Engagement Scale

Pleasure on the Menorah Park Engagement Scale is defined as clearly observable laughing or smiling.For each participant, multiple BRAIN activities were observed during weeks 5-10. Based upon all of these observations that occured during this time period, a single mean score was calculated for each participant on this MPES item. The minimum value for Non Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome. A one-sample t-test was used to assess whether the mean was different from a known Non Engagement mean of 0.28 for standard programming.

Time frame:
Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Pleasure Mean on Menorah Park Engagement Scale
score on a scaleTreatment
Pleasure Mean on Menorah Park Engagement Scale0.72 ± 0.27
SecondaryChange From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)

The Dementia Related Quality of Life Scale is a 28 item scale that examines quality of life in persons with dementia. The score ranges for 28 to 112. Higher scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)
score on a scaleTreatment
Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)0.85 ± 9.4
Statistical analysis
  • Treatment · t-test, 2 sided · p = 0.81
SecondaryChange From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)

The NPI-NH examines 10 types of neuropsychiatric symptoms in persons with dementia, with the FxS score looking creating a composite score that takes into account frequency and severity of the symtoms. The score ranges from 0 to 120. Lower scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)
score on a scaleTreatment
Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)-3.38 ± 6.68
Statistical analysis
  • Treatment · t-test, 2 sided · p = 0.20
SecondaryChange From Baseline to Treatment on the University of California, Los Angels (UCLA) Loneliness Scale

The UCLA Loneliness Scale is a widely used psychological tool designed to measure an individual's subjective feelings of loneliness and social isolation. The 20-item version consists of statements related to social connections, with responses typically rated on a four-point Likert scale (e.g., "Never," "Rarely," "Sometimes," "Often"). Scoring involves summing item responses, with higher scores indicating greater levels of loneliness. The range of total possible score is 20 (least amount of loneliness) to 80 (most amount of loneliness).

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on the University of California, Los Angels (UCLA) Loneliness Scale
score on a scaleTreatment
Change From Baseline to Treatment on the University of California, Los Angels (UCLA) Loneliness Scale-0.71 ± 8.94
Statistical analysis
  • Treatment · t-test, 2 sided · p = 0.83
SecondaryChange From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)

The 15-item Geriatric Depression Scale (GDS-SF) is a screening tool used to assess depressive symptoms in older adults. Each item is answered with a "Yes" or "No"\*\* response, with a total score ranging from 0 to 15, where higher scores indicate greater depressive symptoms. A score of 5 or more\*\* suggests possible depression, warranting further clinical evaluation.

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)
score on a scaleTreatment
Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)-1.00 ± 2.67
Statistical analysis
  • Treatment · t-test, 2 sided · p = 0.320

Adverse events

Collected over 2.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

All participants who enrolled, including those who could not complete due to scheduling conflicts

Age, Continuous
Age, Continuous(years)Treatment
Mean82.40 ± 5.19
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female4
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment
United States10
08

Study locations

1 site
  • Hopeful Aging
    Winchester, Massachusetts 01890, United States
09

References and documents

Study documents

  • Study protocol · Dec 1, 2023
  • Statistical analysis plan · Dec 1, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05516147
Lead sponsor
Hopeful Aging
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Jan 19, 2024
Primary completion
Apr 10, 2024
Completion
Apr 10, 2024
Results posted
Mar 21, 2025
Last update
Mar 21, 2025

Study contacts

Michael Skrajner, MA
principal investigator · The Hearthstone Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion